Passage Bio, Inc. (PASG)
| Market Cap | 18.28M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -45.52M |
| Shares Out | 3.21M |
| EPS (ttm) | -14.35 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 85,301 |
| Open | 5.75 |
| Previous Close | 5.71 |
| Day's Range | 5.65 - 5.75 |
| 52-Week Range | 5.12 - 20.00 |
| Beta | 1.77 |
| Analysts | Buy |
| Price Target | 14.00 (+145.61%) |
| Earnings Date | May 12, 2026 |
About PASG
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding β-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington’s... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for PASG stock is "Buy." The 12-month stock price target is $14.0, which is an increase of 145.61% from the latest price.
News
Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates
PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to natural history, reducing brain atrophy and stabilizing plasma NfL levels
Passage Bio Transcript: TD Cowen 46th Annual Health Care Conference
AAV gene therapy for FTD-GRN is advancing with a focus on earlier-stage patients and a safer, lower dose, showing promising biomarker and safety data. Regulatory discussions are ongoing, and a Huntington’s program is progressing toward clinical candidate selection.
Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights
Enrolled first three FTD-GRN patients in Cohort 3 of ongoing upliFT-D study Treated first FTD-C9orf72 patient with Dose 2 PBFT02 in Cohort 4 of upliFT-D study On track to report updated interim safety...
Passage Bio Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Lead gene therapy program for FTD-GRN shows robust, durable target engagement and favorable safety, with a focus on earlier-stage patients and improved trial design. Huntington's program targets MSH3, with clinical candidate selection expected in H2. Cash runway extends into Q1 2027.
Passage Bio to Participate in Upcoming Investor Conferences
PHILADELPHIA, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases,...
Passage Bio Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
The lead gene therapy program targets early-stage FTD-GRN patients, aiming to raise progranulin levels more effectively than competitors. Encouraged by FDA guidance, the team plans early regulatory engagement and expects key data and feedback in the first half of next year.
Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights
Actively enrolling Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72) patients in ongoing upliFT-D study Aligned with the U.S. Food and Drug Administration (FDA) on an analytical approach to establish comp...
Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference
PHILADELPHIA, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases,...
Passage Bio Transcript: Chardan’s 9th Annual Genetic Medicines Conference
Gene therapy programs for neurodegenerative diseases are advancing with local delivery, AI-driven data analysis, and strong clinical results. Regulatory agencies are increasingly flexible, and access is expected to improve as procedures align with existing hospital practices.
Passage Bio to Participate in Chardan's 9th Annual Genetic Medicines Conference
PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases,...
Passage Bio Transcript: H.C. Wainwright 27th Annual Global Investment Conference
PBFT02, a one-time AAV1 gene therapy for FTD, shows robust, durable increases in progranulin and early signs of slowing neurodegeneration, with a favorable safety profile and strong competitive positioning. Expansion to new patient groups and key regulatory milestones are planned through 2026.
Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference
PHILADELPHIA, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases,...
Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights
Completed dosing of FTD-GRN Cohort 2 in upliFT-D study Reported updated interim data showing that PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma...
Passage Bio Announces 1-for-20 Reverse Stock Split
PHILADELPHIA, July 10, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (“Passage Bio” or the “Company”) (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients...
Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update
PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease progression biomarker, compared to natural history Dose 2, 50% lower than Dose 1, ...
Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights
Treated first FTD-GRN patient with Dose 2 PBFT02 and enrolled second patient; several additional patients being evaluated for trial eligibility Announced presentation of process development data of a ...
Passage Bio Transcript: Leerink Global Healthcare Conference 2025
PBFT02, a one-time AAV1 gene therapy for FTD-GRN, shows durable CSF progranulin elevation and promising early biomarker effects on neurodegeneration. The program is advancing with robust manufacturing, regulatory alignment, and plans for further data readouts in 2025.
Passage Bio Transcript: TD Cowen 45th Annual Healthcare Conference
PBFT02, a one-time AAV1 gene therapy for FTD with granulin mutations, shows durable, elevated CSF progranulin and promising early biomarker effects, with expanded indications and strong manufacturing capabilities. Additional clinical data and regulatory milestones are expected through 2026.
Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights
Interim data from Dose 1 PBFT02 demonstrated durable, elevated CSF PGRN and early evidence of reduction in plasma NfL levels, a disease progression biomarker, as compared to published natural history ...
Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates
PBFT02 demonstrated durable, elevated CSF PGRN levels and early evidence of reduction in plasma NfL levels, a disease progression biomarker, compared to published natural history data
Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
PHILADELPHIA , Nov. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases...
Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference
Preclinical data demonstrated that an AAV1 vector achieved superior human progranulin levels in the CSF as compared to AAV5 and AAVhu68 (an AAV9 variant)
Passage Bio Transcript: Chardan's 8th Annual Genetic Medicines Conference
PBFT02, a one-time AAV1 gene therapy for FTD-GRN, shows high, durable, and consistent CSF progranulin levels with a favorable safety profile. Regulatory feedback is positive, with pivotal discussions planned and expansion to FTD-C9 underway. Differentiation is based on durability and convenience.
Passage Bio to Present at Chardan's 8th Annual Genetic Medicines Conference
PHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases...
Passage Bio Welcomes Tom Kassberg to Board of Directors
PHILADELPHIA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases...